Ultimovacs Valuation

Is ULTIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ULTIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ULTIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ULTIO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ULTIO?

Key metric: As ULTIO is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ULTIO. This is calculated by dividing ULTIO's market cap by their current book value.
What is ULTIO's PB Ratio?
PB Ratio	0.4x
Book	NOK 217.46m
Market Cap	NOK 77.76m

ULTIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ULTIO's PB Ratio compare to its peers?

The above table shows the PB ratio for ULTIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	6.3x
ROQ Roquefort Therapeutics	1.1x	n/a	UK£5.6m
GENF Genflow Biosciences	7.1x	n/a	UK£6.1m
APTA Aptamer Group	7.4x	n/a	UK£6.5m
CIZ Cizzle Biotechnology Holdings	9.5x	n/a	UK£7.5m
ULTIO Ultimovacs	0.4x	30.7%	NOK 77.8m

Price-To-Book vs Peers: ULTIO is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (2.9x).

Price to Book Ratio vs Industry

How does ULTIO's PB Ratio compare vs other companies in the GB Biotechs Industry?

5 Companies	Price / Book	Estimated Growth	Market Cap
Industry Avg.	n/a	37.0%
ULTIO Ultimovacs	0.4x	30.7%	US$7.25m
DEST Destiny Pharma	0.3x	-15.5%	US$5.85m
BDRX Biodexa Pharmaceuticals	0.5x	n/a	US$4.42m

5 Companies		Estimated Growth	Market Cap
Industry Avg.	n/a	37.0%
ULTIO Ultimovacs	0.4x	30.7%	US$7.25m

No more companies

Price-To-Book vs Industry: ULTIO is good value based on its Price-To-Book Ratio (0.4x) compared to the UK Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is ULTIO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ULTIO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ULTIO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

1.0%

13.3%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

-13.4%

17.3%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

-1.6%

-6.1%